Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard.

Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. 
Former clinical assets MESUPRON® and REDECTANE® have been partnered.

Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

Heidelberg Pharma Research GmbH

Org chart

Similar companies